Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03682068
Title Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer (NILE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

urethra transitional cell carcinoma

Therapies

Carboplatin + Durvalumab + Gemcitabine

Carboplatin + Durvalumab + Gemcitabine + Tremelimumab

Cisplatin + Durvalumab + Gemcitabine

Cisplatin + Durvalumab + Gemcitabine + Tremelimumab

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Age Groups: senior | adult
Covered Countries USA | ITA | ESP | CAN | AUS


No variant requirements are available.